Work

Phase 2 Study of Allogeneic Hematopoietic Cell Transplant (HCT) Following Intermediate-Intensity Fludarabine and Busulfan x 4 (FluBu4) Conditioning for High-Risk or Advanced Multiple Myeloma

Year: 2013

Type: article

Abstract: The treatment of advanced and poor-risk multiple myeloma (MM) is still a major challenge and no therapy has proven to be curative or effective long term. Although allogeneic HCT has curative potential, the outcomes remain poor due to high treatment-related mortality (TRM) after full-intensity conditioning, high relapse rate after reduced-intensity regimens and possibly other disease-specific issues. Under an IRB approved protocol at the University of Michigan, we enrolled 22 patients onto a phase 2 trial exploring the feasibility and efficacy of an intermediate-intensity conditioning with fludarabine and busulfan x 4 (FluBu4) [fludarabine 40mg/m2/day and busulfan 3.2 mg/kg/day IV x 4 days], followed by allogeneic HCT between 2008 and 2011.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2012.11.302